Pages that link to "Item:Q4667490"
From MaRDI portal
The following pages link to A Curve‐Free Method for Phase I Clinical Trials (Q4667490):
Displayed 20 items.
- Incorporating a patient dichotomous characteristic in cancer phase I clinical trials using escalation with overdose control (Q454783) (← links)
- The treatment versus experimentation dilemma in dose finding studies (Q538132) (← links)
- Stochastic approximation and modern model-based designs for dose-finding clinical trials (Q903289) (← links)
- Continual reassessment and related dose-finding designs (Q903292) (← links)
- Design efficiency in dose finding studies (Q956828) (← links)
- EM-type algorithms for computing restricted MLEs in multivariate normal distributions and multivariatet-distributions (Q1023837) (← links)
- Escalation with overdose control using ordinal toxicity grades for cancer phase I clinical trials (Q1929691) (← links)
- Bayesian hierarchical random-effects meta-analysis and design of phase I clinical trials (Q2080762) (← links)
- Flexible link continual reassessment methods for trivariate binary outcome phase I/II trials (Q2320854) (← links)
- A comparative study of the dose-response analysis with application to the target dose estimation (Q2323265) (← links)
- Sequential Monte Carlo for Bayesian sequentially designed experiments for discrete data (Q2359487) (← links)
- An application of reinforced urn processes to determining maximum tolerated dose (Q2373664) (← links)
- Adaptive clinical trial designs for phase I cancer studies (Q2452091) (← links)
- On the Use of Nonparametric Curves in Phase I Trials with Low Toxicity Tolerance (Q3078934) (← links)
- Curve-Free and Model-Based Continual Reassessment Method Designs (Q3078936) (← links)
- A Simple Technique to Evaluate Model Sensitivity in the Continual Reassessment Method (Q3079010) (← links)
- Bayesian Optimal Designs for Phase I Clinical Trials (Q3079157) (← links)
- A Latent Contingency Table Approach to Dose Finding for Combinations of Two Agents (Q3183236) (← links)
- Bayesian Dose-Finding in Phase I/II Clinical Trials Using Toxicity and Efficacy Odds Ratios (Q3436524) (← links)
- Impact of different model structure and prior distribution in continual reassessment method (Q5087922) (← links)
